高位結紮術併用本幹フォーム硬化療法

要約:大伏在静脈1505 例,1951 肢,小伏在静脈205 例,219 肢に対し高位結紮術併用本幹フォーム硬化療法を行った.生命表による大伏在静脈累積閉塞率は5 年85.0%,10 年52.1%であった.伏在膝窩静脈接合部(SPJ)の1 年閉塞率は85.5%であった.比例Cox モデルを用いた多変量解析で,大伏在静脈閉塞率は1%ポリドカノール(ハザード比2.59 vs 3%ポリドカノール),BMI 30 以上(ハザード比3.21 vs BMI 25 未満)で劣り,SPJ 閉塞率は空置SPJ 長70 mm 以上(ハザード比5.94 vs 30 mm 未満)で劣っていた.年齢,性,左右,CEAP...

Full description

Saved in:
Bibliographic Details
Published in静脈学 Vol. 26; no. 3; pp. 256 - 264
Main Author 戸島, 雅宏
Format Journal Article
LanguageJapanese
Published 日本静脈学会 2015
Subjects
Online AccessGet full text
ISSN0915-7395
2186-5523
DOI10.7134/phlebol.14-27

Cover

Abstract 要約:大伏在静脈1505 例,1951 肢,小伏在静脈205 例,219 肢に対し高位結紮術併用本幹フォーム硬化療法を行った.生命表による大伏在静脈累積閉塞率は5 年85.0%,10 年52.1%であった.伏在膝窩静脈接合部(SPJ)の1 年閉塞率は85.5%であった.比例Cox モデルを用いた多変量解析で,大伏在静脈閉塞率は1%ポリドカノール(ハザード比2.59 vs 3%ポリドカノール),BMI 30 以上(ハザード比3.21 vs BMI 25 未満)で劣り,SPJ 閉塞率は空置SPJ 長70 mm 以上(ハザード比5.94 vs 30 mm 未満)で劣っていた.年齢,性,左右,CEAP 分類臨床徴候,術前深部静脈不全,大伏在静脈直径,混合気体(空気or 炭酸ガス),SPJ 直径の各因子は閉塞率に有意な影響を認めなかった.大伏在静脈閉塞の長期成績は良好で有用な治療手段と考えている.SPJ 閉塞の短期成績は良好で今後長期成績の検討が必要である.
AbstractList 「要約」:大伏在静脈1505例, 1951肢, 小伏在静脈205例, 219肢に対し高位結紮術併用本幹フォーム硬化療法を行った. 生命表による大伏在静脈累積閉塞率は5年85.0%, 10年52.1%であった. 伏在膝窩静脈接合部(SPJ)の1年閉塞率は85.5%であった. 比例Coxモデルを用いた多変量解析で, 大伏在静脈閉塞率は1%ポリドカノール(ハード比2.59 vs 3%ポリドカノール), BMI 30以上(ハザード比3.21 vs BMI 25未満)で劣り, SPJ閉塞率は空置SPJ長70mm以上(ハザード比5.94 vs 30mm未満)で劣っていた. 年齢, 性, 左右, CEAP分類臨床徴候, 術前深部静脈不全, 大伏在静脈直径, 混合気体(空気or炭酸ガス), SPJ直径の各因子は閉塞率に有意な影響を認めなかった. 大伏在静脈閉塞の長期成績は良好で有用な治療手段と考えている. SPJ閉塞の短期成績は良好で今後長期成績の検討が必要である.
要約:大伏在静脈1505 例,1951 肢,小伏在静脈205 例,219 肢に対し高位結紮術併用本幹フォーム硬化療法を行った.生命表による大伏在静脈累積閉塞率は5 年85.0%,10 年52.1%であった.伏在膝窩静脈接合部(SPJ)の1 年閉塞率は85.5%であった.比例Cox モデルを用いた多変量解析で,大伏在静脈閉塞率は1%ポリドカノール(ハザード比2.59 vs 3%ポリドカノール),BMI 30 以上(ハザード比3.21 vs BMI 25 未満)で劣り,SPJ 閉塞率は空置SPJ 長70 mm 以上(ハザード比5.94 vs 30 mm 未満)で劣っていた.年齢,性,左右,CEAP 分類臨床徴候,術前深部静脈不全,大伏在静脈直径,混合気体(空気or 炭酸ガス),SPJ 直径の各因子は閉塞率に有意な影響を認めなかった.大伏在静脈閉塞の長期成績は良好で有用な治療手段と考えている.SPJ 閉塞の短期成績は良好で今後長期成績の検討が必要である.
Author 戸島, 雅宏
Author_xml – sequence: 1
  fullname: 戸島, 雅宏
  organization: かみいち総合病院血管外科
BookMark eNo9kMtKw0AYhQepYK1d-hipc5_OUopWoeBG18NkMrUJaVKSunDbbhUErSi4sDvF4ka7KNin6SX6FqZU5MA5HH74fjjboBDFkQVgF8GKQITudVqhdeOwgqiDxQYoYlTlDmOYFEARSsQcQSTbAuU09V3IEKeIUVgE5OftYT69zsY32ef79_B2Ph1ndy_Lp9FiMpn1B7Pe66z_Nes_Z8PR4uo-e-wtPwY7YLOpw9SW_7IEzg4PTmtHTuOkflzbbzgBpkI6VewyyqgHXS6w8DikUEsjm9ASrT2qpbWQSKONy7WmGFPUNLlcZrTklhFSAvU1t2093-gwjkI_siqIL5Io_6tsTIMg7rQUhogpCDGHJA-uIGYr4xQzgSWROam2JgVpV59b1Un8tk4ulU66vgnzvh5PYa7IyhBVWPxfTUsnKtDkF1TTfp0
ContentType Journal Article
Copyright 2015 日本静脈学会
Copyright_xml – notice: 2015 日本静脈学会
CorporateAuthor かみいち総合病院血管外科
CorporateAuthor_xml – name: かみいち総合病院血管外科
DOI 10.7134/phlebol.14-27
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
EISSN 2186-5523
EndPage 264
ExternalDocumentID eo4jjoph_2015_002603_006_0256_02642572939
article_phlebol_26_3_26_14_27_article_char_ja
GroupedDBID ABJNI
ALMA_UNASSIGNED_HOLDINGS
GROUPED_DOAJ
JSF
MOJWN
RJT
ID FETCH-LOGICAL-j2479-82b5454d0b6727d6040a9c9f0e3aad4a9ee039cacb6aa42241fcfcfb5ca96e533
ISSN 0915-7395
IngestDate Thu Jul 10 16:18:53 EDT 2025
Wed Sep 03 06:23:10 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language Japanese
License https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j2479-82b5454d0b6727d6040a9c9f0e3aad4a9ee039cacb6aa42241fcfcfb5ca96e533
OpenAccessLink https://www.jstage.jst.go.jp/article/phlebol/26/3/26_14-27/_article/-char/ja
PageCount 9
ParticipantIDs medicalonline_journals_eo4jjoph_2015_002603_006_0256_02642572939
jstage_primary_article_phlebol_26_3_26_14_27_article_char_ja
PublicationCentury 2000
PublicationDate 2015
20150000
PublicationDateYYYYMMDD 2015-01-01
PublicationDate_xml – year: 2015
  text: 2015
PublicationDecade 2010
PublicationTitle 静脈学
PublicationTitleAlternate 静脈学
PublicationYear 2015
Publisher 日本静脈学会
Publisher_xml – name: 日本静脈学会
References 14) 岩井武尚,平井正文監修:フォーム硬化療法の手引き(第2 回ヨーロッパコンセンサスミーティング2006 翻訳版),2010,p. 22
16) Künzlberger B, Pieck C, Altmeyer P, et al: Migraine ophthalmique with reversible scotomas after sclerotherapy with liquid 1% polidocanol. Dermatol Surg 2006; 32: 1410–1413
8) Darvall KA, Bate GR, Silverman SH, et al: Medium-term results of ultrasound-guided foam sclerotherapy for small saphenous varicose veins. Br J Surg 2009; 96: 1268–1273
15) Guex JJ, Allaert FA, Gillet JL, et al: Immediate and mid-term complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg 2005; 31: 123–128; discussion 128
21) Gillet JL, Lausecker M, Sica M, et al: Is the treatment of the small saphenous veins with foam sclerotherapy at risk of deep vein thrombosis? Phlebology 2014; 29: 600–607
5) Rasmussen LH, Lawaetz M, Bjoern L, et al: Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Br J Surg 2011; 98: 1079–1087
20) Georgiev MJ: Postsclerotherapy hyperpigmentations: a one-year follow-up. Dermatol Surg Oncol 1990; 16: 608–610
4) Hartmann K, Klode J, Pfister R, et al: Recurrent varicose veins: sonography-based re-examination of 210 patients 14 years after ligation and saphenous vein stripping. VASA 2006; 35: 21–26
18) Scultetus AH, Villavicencio JL, Kao TC, et al: Micro-thrombectomy reduces postsclerotherapy pigmentation: multicenter randomized trial. J Vasc Surg 2003; 38: 896–903
12) Morrison N, Neuhardt DL, Rogers CR, et al: Comparisons of side effects using air and carbon dioxide foam for endovenous chemical ablation. J Vasc Surg 2008; 47: 830–836
17) Willenberg T, Smith PC, Shepherd A, et al: Visual disturbance following sclerotherapy for varicose veins, reticular and telangiectasias: a systematic literature review. Phlebology 2013; 28: 123–131
7) Smith PC: Chronic venous disease treated by ultrasound guided foam sclerotherapy. Eur J Vasc Endovasc Surg 2006; 32: 577–583
3) Timperman PE: Prospective evaluation of higher energy great saphenous vein endovenous laser treatment. J Vasc Interv Radiol 2005; 16: 791–794
10) Hartmann K, Harms L, Simon M: Reversible neurological deficit after foam sclerotherapy. Eur J Vasc Endovasc Surg 2009; 38: 648–649
13) 戸島雅宏,藤縄摂子:CO2 法vs 空気法:フォーム硬化療法による下肢静脈瘤治療成績.静脈学2009; 20: 163
1) 岩田博英,佐戸川弘之,坂田雅宏,他:下肢静脈瘤―本邦における静脈疾患に関するSurvey XII―.静脈学 2013; 24: 432–439
9) Forlee MV, Grouden M, Moore DJ, et al: Stroke after varicose vein foam injection sclerotherapy. J Vasc Surg 2006; 43: 162–164
6) Myers KA, Jolley D, Clough A, et al: Outcome of ultrasound-guided sclerotherapy for varicose veins: medium-term results assessed by ultrasound surveillance. Eur J Vasc Endovasc Surg 2007; 33: 116–121
2) Rabe E, Breu FX, Cavezzi A, et al: European guidelines for sclerotherapy in chronic venous disorders. Phlebology 2014; 29: 338–354
11) 岩井武尚,平井正文監修:フォーム硬化療法の手引き(第2 回ヨーロッパコンセンサスミーティング2006 翻訳版),2010,p. 15
19) Alòs J, Carreño P, López JA, et al: Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. Eur J Vasc Endovasc Surg 2006; 31: 101–107
References_xml – reference: 14) 岩井武尚,平井正文監修:フォーム硬化療法の手引き(第2 回ヨーロッパコンセンサスミーティング2006 翻訳版),2010,p. 22
– reference: 10) Hartmann K, Harms L, Simon M: Reversible neurological deficit after foam sclerotherapy. Eur J Vasc Endovasc Surg 2009; 38: 648–649
– reference: 1) 岩田博英,佐戸川弘之,坂田雅宏,他:下肢静脈瘤―本邦における静脈疾患に関するSurvey XII―.静脈学 2013; 24: 432–439
– reference: 21) Gillet JL, Lausecker M, Sica M, et al: Is the treatment of the small saphenous veins with foam sclerotherapy at risk of deep vein thrombosis? Phlebology 2014; 29: 600–607
– reference: 3) Timperman PE: Prospective evaluation of higher energy great saphenous vein endovenous laser treatment. J Vasc Interv Radiol 2005; 16: 791–794
– reference: 13) 戸島雅宏,藤縄摂子:CO2 法vs 空気法:フォーム硬化療法による下肢静脈瘤治療成績.静脈学2009; 20: 163
– reference: 19) Alòs J, Carreño P, López JA, et al: Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. Eur J Vasc Endovasc Surg 2006; 31: 101–107
– reference: 2) Rabe E, Breu FX, Cavezzi A, et al: European guidelines for sclerotherapy in chronic venous disorders. Phlebology 2014; 29: 338–354
– reference: 17) Willenberg T, Smith PC, Shepherd A, et al: Visual disturbance following sclerotherapy for varicose veins, reticular and telangiectasias: a systematic literature review. Phlebology 2013; 28: 123–131
– reference: 16) Künzlberger B, Pieck C, Altmeyer P, et al: Migraine ophthalmique with reversible scotomas after sclerotherapy with liquid 1% polidocanol. Dermatol Surg 2006; 32: 1410–1413
– reference: 5) Rasmussen LH, Lawaetz M, Bjoern L, et al: Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Br J Surg 2011; 98: 1079–1087
– reference: 4) Hartmann K, Klode J, Pfister R, et al: Recurrent varicose veins: sonography-based re-examination of 210 patients 14 years after ligation and saphenous vein stripping. VASA 2006; 35: 21–26
– reference: 11) 岩井武尚,平井正文監修:フォーム硬化療法の手引き(第2 回ヨーロッパコンセンサスミーティング2006 翻訳版),2010,p. 15
– reference: 9) Forlee MV, Grouden M, Moore DJ, et al: Stroke after varicose vein foam injection sclerotherapy. J Vasc Surg 2006; 43: 162–164
– reference: 18) Scultetus AH, Villavicencio JL, Kao TC, et al: Micro-thrombectomy reduces postsclerotherapy pigmentation: multicenter randomized trial. J Vasc Surg 2003; 38: 896–903
– reference: 15) Guex JJ, Allaert FA, Gillet JL, et al: Immediate and mid-term complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg 2005; 31: 123–128; discussion 128
– reference: 6) Myers KA, Jolley D, Clough A, et al: Outcome of ultrasound-guided sclerotherapy for varicose veins: medium-term results assessed by ultrasound surveillance. Eur J Vasc Endovasc Surg 2007; 33: 116–121
– reference: 7) Smith PC: Chronic venous disease treated by ultrasound guided foam sclerotherapy. Eur J Vasc Endovasc Surg 2006; 32: 577–583
– reference: 8) Darvall KA, Bate GR, Silverman SH, et al: Medium-term results of ultrasound-guided foam sclerotherapy for small saphenous varicose veins. Br J Surg 2009; 96: 1268–1273
– reference: 12) Morrison N, Neuhardt DL, Rogers CR, et al: Comparisons of side effects using air and carbon dioxide foam for endovenous chemical ablation. J Vasc Surg 2008; 47: 830–836
– reference: 20) Georgiev MJ: Postsclerotherapy hyperpigmentations: a one-year follow-up. Dermatol Surg Oncol 1990; 16: 608–610
SSID ssib051641540
ssj0002909513
ssib058493114
ssib002004226
Score 1.9821824
Snippet 要約:大伏在静脈1505 例,1951 肢,小伏在静脈205 例,219 肢に対し高位結紮術併用本幹フォーム硬化療法を行った.生命表による大伏在静脈累積閉塞率は5 年85.0%,10 年52.1%であった.伏在膝窩静脈接合部(SPJ)の1 年閉塞率は85.5%であった.比例Cox...
「要約」:大伏在静脈1505例, 1951肢, 小伏在静脈205例, 219肢に対し高位結紮術併用本幹フォーム硬化療法を行った. 生命表による大伏在静脈累積閉塞率は5年85.0%, 10年52.1%であった. 伏在膝窩静脈接合部(SPJ)の1年閉塞率は85.5%であった. 比例Coxモデルを用いた多変量解析で,...
SourceID medicalonline
jstage
SourceType Publisher
StartPage 256
SubjectTerms フォーム硬化療法
伏在膝窩静脈接合部
大伏在静脈
閉塞率
高位結紮術併用本幹硬化療法
Title 高位結紮術併用本幹フォーム硬化療法
URI https://www.jstage.jst.go.jp/article/phlebol/26/3/26_14-27/_article/-char/ja
http://mol.medicalonline.jp/en/journal/download?GoodsID=eo4jjoph/2015/002603/006&name=0256-0264j
Volume 26
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX 静脈学, 2015, Vol.26(3), pp.256-264
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NaxQxFB-WehFEFBXrFz2Y4-jOTJJJwIMzu1OKoKcWeguZL8pQu6VuLx48dK8KglYUPNibYvGiPRTsH-HfsG1X_wvfS2bXaVGwyi4hJHlvXuZlkl8-3ovj3AzSTPhF7rlhqVOX6pK6WmShWzBOQ4AHTKTmgOwDPrdA7y2yxVbrW-PU0no_vZU9_q1dyb9oFdJAr2glewLNTphCAsRBvxCChiH8Kx2TRJIoJlKQhJK4S0SXJCGJGZFtE6EkSkgiSOQRGdRlIBeyJGQBFSeyQ6IOSRiJJf6TgIiASGYiPonGKXGnjkSGMzC0VKJDJDcMJZYHhjGSNyEvCim7WAAkEQBdBRJGXRJNFgWRDpJjkwMMYo6aN4QxEcyUT4iYbS5RWPNM05xMPUAo1qjQH59pXgNIHTUXKT3m4laiHa1MGl6i5TJmrZTHfbi1uq_batDskBlvjO2-9Zh-fNhAe1q863hpGfr4ZRg8XOuv4Jgn7lrPqi6nfK4CDDyq_FCNc9FaTlUA2U_5YejhKdP7T5JfiMg4XZsgQAazVQCxky4T4KAMvHpjG8GELxEDm3MS43dhPcWizLePSAwYqoIZBbqKOPPQ7vJZbysNwDR_zjlbz3RmIivweadV6QtO8OPj6_29Z6Od56Mvn75vvdjf2xm9fH_4dvtgd3c42BxufBgOvg4H70Zb2wdPX43ebBx-3rzoLMwm8505t763w618GkpX-Cngcpq3U9zmzzmME1pmsmwXgdY51bIo2oHMdJZyrSliyDKDX8oyLXkB849LztRKb6W47MxwzViR5V5bi5ICX82ZzHmRhl7JM5i5TDt3bJ3VqnXOok6kpGnn7pE3peqP-5EqerSqeqtLCtuzMp73AmXOgEKLgoDjWAdQWV75PwmuOqfxCXZR75oz1V9bL64DzO2nN0zD-QmTIJVU
linkProvider ISSN International Centre
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E9%AB%98%E4%BD%8D%E7%B5%90%E7%B4%AE%E8%A1%93%E4%BD%B5%E7%94%A8%E6%9C%AC%E5%B9%B9%E3%83%95%E3%82%A9%E3%83%BC%E3%83%A0%E7%A1%AC%E5%8C%96%E7%99%82%E6%B3%95&rft.jtitle=%E9%9D%99%E8%84%88%E5%AD%A6&rft.au=%E6%88%B8%E5%B3%B6%2C+%E9%9B%85%E5%AE%8F&rft.date=2015&rft.pub=%E6%97%A5%E6%9C%AC%E9%9D%99%E8%84%88%E5%AD%A6%E4%BC%9A&rft.issn=0915-7395&rft.eissn=2186-5523&rft.volume=26&rft.issue=3&rft.spage=256&rft.epage=264&rft_id=info:doi/10.7134%2Fphlebol.14-27&rft.externalDocID=article_phlebol_26_3_26_14_27_article_char_ja
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0915-7395&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0915-7395&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0915-7395&client=summon